文献速递瓣膜外科

微创二尖瓣手术治疗二尖瓣脱垂:纤维弹性缺陷与Barlow病的比较

Minimally invasive mitral valve surgery for mitral valve prolapse: a comparison between fibro-elastic deficiency and Barlow's disease.
PubMed 文献 · Interdiscip Cardiovasc Thorac Surg · 2025-01-01

本研究比较微创二尖瓣修复术在Barlow病与纤维弹性缺陷(FED)患者中的中期结果。2008年至2021年间246例退行性二尖瓣脱垂患者接受微创修复,其中FED 180例、Barlow病66例。尽管Barlow病患者更年轻且脱垂更复杂,10年生存率、再次手术率和复发率与FED患者无显著差异。

要点

  • 微创二尖瓣修复在Barlow病中可获得与FED相当的中期结果。
  • Barlow病患者更年轻且二尖瓣脱垂更复杂,但10年再次手术率无显著差异。
  • 10年二尖瓣反流复发率Barlow病较高但无统计学差异。

核心结论

  • 尽管Barlow病患者二尖瓣脱垂范围更广,微创二尖瓣修复的中期结果与FED患者相当。

主要发现

  • Barlow病患者显著更年轻(Barlow:58岁(IQR 47-67);FED:68岁(IQR 60-76),P < 0.001),且二尖瓣脱垂较FED患者更复杂。
  • 总体30天死亡率为0.4%。
  • Barlow病和FED患者10年生存率分别为78.8 ± 11.3%和64.5 ± 7.4%(P = 0.161)。
  • 10年累积再次手术率Barlow病与FED相当(FED:9.7 ± 3.1%;Barlow:8.0 ± 4.7%,P = 0.645)。
  • 二尖瓣反流≥2级复发率总体5年和10年分别为3.0 ± 1.4%和6.8 ± 3.1%;10年时Barlow病较高但无显著差异(FED:3.3 ± 1.7%;Barlow:11.1 ± 8.7%,P = 0.765)。

临床怎么用

  • 微创二尖瓣修复可用于Barlow病患者,其中期结果与FED患者相当。
  • 集中手术经验以提高外科医生技术水平有助于获得与高容量中心相当的结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Within the spectrum of degenerative mitral valve (MV) prolapse, Barlow's disease remains a risk factor for suboptimal long-term outcomes after MV repair (MVr). This study reports on the results of MVr through minimally invasive surgery benchmarking patients with Barlow's disease to fibro-elastic deficiency (FED). METHODS: Between July 2008 and December 2021, 246 patients underwent MVr for degenerative MV prolapse via minimally invasive surgery, including 180 FED and 66 Barlow patients. Study end-points focused on 10-year survival, MV reoperation and recurrence of MV regurgitation ≥grade 2. RESULTS: Barlow patients were significantly younger (Barlow: 58 years (IQR 47-67); FED: 68 years (IQR 60-76), P < 0.001), showing more complex MV prolapse than FED patients. The overall 30 day-mortality was 0.4%. Survival at 10 years was 78.8 ± 11.3% and 64.5 ± 7.4% (P = 0.161) in Barlow and FED patients, respectively. The cumulative incidence of MV reoperation at 10 years was comparable between Barlow and FED patients (FED: 9.7 ± 3.1%; Barlow: 8.0 ± 4.7%, P = 0.645). The cumulative incidence of mitral regurgitation recurrence ≥grade 2 was 3.0 ± 1.4% and 6.8 ± 3.1% at 5 and 10 years overall. Mitral regurgitation recurrence rate at 10 years was higher in Barlow patients, but the difference was not significant (FED: 3.3 ± 1.7% at 10 years; Barlow: 11.1 ± 8.7% at 10 years, P = 0.765). CONCLUSIONS: Despite more extensive MV prolapse in Barlow patients, MVr through minimally surgical access can be achieved with a mid-term outcome comparable to patients with FED. Concentrating the expertise to increase the individual surgeon's experience for surgical approach as the MV procedure itself allowed to achieve outcome results concurrent with those reported by high-volume centres.

来源:Interdiscip Cardiovasc Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Huyghe S, Colpaert B, Czapla J, et al. Minimally invasive mitral valve surgery for mitral valve prolapse: a comparison between fibro-elastic deficiency and Barlow's disease. Interdiscip Cardiovasc Thorac Surg. 2025. PMID: 39999032. doi:10.1093/icvts/ivaf041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。